Evidence map›Paper›PMID 41149454›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study.

Ali Erhan Eren, Asim Armagan Aydin, Eren Erdi Aksaray, Arda Durak, Ahmet Unlu, Mahmut Ekrem Islamoglu, Banu Ozturk, Mustafa Yildiz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ali Erhan ErenDepartment of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.
Asim Armagan AydinDepartment of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.ORCID 0000-0001-8749-9825
Eren Erdi AksarayDepartment of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.ORCID 0000-0003-1074-1016
Arda DurakDepartment of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.ORCID 0009-0008-0159-2497
Ahmet UnluDepartment of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.ORCID 0000-0001-6654-3815
Mahmut Ekrem IslamogluDepartment of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.ORCID 0000-0003-0693-0666
Banu OzturkDepartment of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.
Mustafa YildizDepartment of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrothelial carcinoma of the bladder (UCB) demonstrates considerable heterogeneity, with markedly varying outcomes between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The pan-immune-inflammation value (PIV), derived from routine hematological parameters, has emerged as a novel biomarker reflecting systemic inflammation and immune dysregulation. This pilot, exploratory analysis evaluated the prognostic relevance of the PIV in UCB and contextualized PIV against other inflammation-based indices.

methodsWe retrospectively analyzed 119 patients with histologically confirmed UCB who were treated between 2019 and 2024. PIV was calculated as (neutrophils × platelets × monocytes) ÷ lymphocytes. Additional indices included the NLR, SII, SIRI, and PLR. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier analysis, and prognostic factors were assessed using Cox regression.

resultsAmong 119 patients (median age, 72 years; 88% male), 68 were diagnosed with NMIBC and 51 with MIBC. Elevated PIV levels were significantly associated with NMIBC progression to MIBC (

conclusionElevated PIV levels predict adverse survival outcomes and progression in UCB, underscoring its potential as a cost-effective and accessible biomarker for risk stratification. Prospective validation in larger cohorts is warranted to confirm its role in personalized patient management.

Indexed as

Carcinoma, Transitional CellInflammationNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsAgedAged, 80 and overDisease ProgressionFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedPilot ProjectsPrognosisProgression-Free Survivalbiomarkerbladder cancermuscle invasivenon-muscle invasivepan-immune-inflammation valueprognosissurvivalurothelial carcinoma

Identifiers

PMID41149454
PMCPMC12564454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.